ResMed said revenue for the 3 months ended December 31, 2024 was $1,282.1 million, up 10% from $1,162.8 million in the prior year period, and up 10% on a constant currency basis.

1. 01

   ResMed said revenue for the 3 months ended December 31, 2024 was $1,282.1 million, up 10% from $1,162.8 million in the prior year period, and up 10% on a constant currency basis.

2. 02

   The company said gross margin for the quarter improved 300 basis points to 58.6%, income from operations increased 52%, and the prior year period included $64.2 million of restructuring-related charges.

3. 03

   ResMed said net income for the quarter was $344.6 million, up 65% from $208.8 million in the prior year period, diluted earnings per share was $2.34, and non-GAAP diluted earnings per share was $2.43.

4. 04

   The company said operating cash flow for the quarter was $309 million, it paid $78 million in dividends and repurchased 307,000 shares for $75 million, and its board declared a quarterly cash dividend of $0.53 per share.

Analysis scope · Filing body and confirmed press-release exhibitWe analyzed the filing body and confirmed exhibits. This is not a review of other exhibits, investor presentations or the full earnings call.

AI summarized the filing and translated the summary into English; it may differ from the original. For reference only, not investment advice. AI translated the published Korean report into English. Figures are copied as filed, not recalculated.

Original filing

The filing as submitted to SEC EDGAR. You can check the figures and statements of this summary against it.